MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Fulgent Genetics Inc

Fermé

SecteurSoins de santé

19.17 -1.84

Résumé

Variation du prix de l'action

24h

Actuel

Min

19.1

Max

19.31

Chiffres clés

By Trading Economics

Revenu

-5.7M

-12M

Ventes

-2.8M

73M

Marge bénéficiaire

-16.197

Employés

1,313

EBITDA

-2M

-12M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+16.76% upside

Dividendes

By Dow Jones

Prochains Résultats

1 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

15M

587M

Ouverture précédente

21.01

Clôture précédente

19.17

Sentiment de l'Actualité

By Acuity

50%

50%

131 / 376 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

Fulgent Genetics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 juil. 2025, 22:19 UTC

Acquisitions, Fusions, Rachats

FCC Approves U.S. Cellular Sale to T-Mobile

11 juil. 2025, 17:28 UTC

Principaux Mouvements du Marché

SharpLink Gaming Gains on Ethereum Purchase

11 juil. 2025, 16:57 UTC

Résultats

BASF Cuts Outlook on Global Economy Uncertainty

12 juil. 2025, 02:24 UTC

Acquisitions, Fusions, Rachats

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12 juil. 2025, 02:05 UTC

Acquisitions, Fusions, Rachats

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12 juil. 2025, 02:05 UTC

Acquisitions, Fusions, Rachats

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12 juil. 2025, 02:05 UTC

Acquisitions, Fusions, Rachats

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11 juil. 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 juil. 2025, 19:46 UTC

Acquisitions, Fusions, Rachats

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 juil. 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 juil. 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 juil. 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 juil. 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 juil. 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 juil. 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11 juil. 2025, 16:42 UTC

Résultats

BASF Cuts Outlook on Global Economic Uncertainty

11 juil. 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 juil. 2025, 16:05 UTC

Résultats

BASF Will Publish Half-Year Results on July 30

11 juil. 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

11 juil. 2025, 16:04 UTC

Market Talk

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 juil. 2025, 16:03 UTC

Résultats

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 juil. 2025, 16:02 UTC

Résultats

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 juil. 2025, 16:01 UTC

Résultats

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 juil. 2025, 16:00 UTC

Résultats

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 juil. 2025, 15:59 UTC

Résultats

BASF Cuts 2025 Earnings View

11 juil. 2025, 15:58 UTC

Résultats

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 juil. 2025, 15:57 UTC

Résultats

BASF 2Q EBIT Before Special Items EUR810M

11 juil. 2025, 15:54 UTC

Résultats

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 juil. 2025, 15:54 UTC

Résultats

BASF 2Q Sales Fell 2.1% on Year

11 juil. 2025, 15:53 UTC

Résultats

BASF 2Q Sales EUR15.77B

Comparaison

Variation de prix

Fulgent Genetics Inc prévision

Objectif de Prix

By TipRanks

16.76% hausse

Prévisions sur 12 Mois

Moyen 22.5 USD  16.76%

Haut 25 USD

Bas 19.5 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

1

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

17.32 / 19.04Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

131 / 376Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.